Developer docs
API playgroundTry for free, no card

Search company profiles

Maple Health Group

Full company profile

uuid0009mtm

Namestring
Maple Health Group
Legal namestring
Maple Health Group, LLC
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Maple Health Group is a global strategy consulting firm founded in 2015 and headquartered in New York, specializing in Health Economics and Market Access (HEOR) advisory services for pharmaceutical, biotechnology, and medical device companies. The firm is organized around three integrated service lines: Market Access and Value Strategy (therapeutic-area landscape assessments, strategic evidence generation planning, payer research, and market access training), Economic Modelling and Evidence Synthesis (cost-effectiveness, cost-utility, budget impact and microsimulation models, systematic literature reviews, Bayesian network meta-analyses, MAICs, and HTA strategy and submissions), and Value Communications (global value dossiers, AMCP dossiers, payer value propositions, scientific publications, and conference materials). Underlying technical assets include proprietary Excel/VBA-based economic models, web-based pricing and access monitoring tools, and the co-developed STEER structured expert elicitation methodology that has been referenced by multiple HTA agencies.

The firm generates revenue through project-based, quote-based professional services engagements sold directly to enterprise pharma, biotech, and med-device clients; specific pricing is not publicly disclosed. Delivery is performed by a globally distributed team of senior consultants and PhD-level health economists operating from nearly a dozen countries and fluent in over 15 languages, including former NICE Technology Appraisal Committee members, ex-pharma HEOR leaders from Biogen, Pfizer, Daiichi-Sankyo, J&J, and EMD Serono, and alumni of CBPartners, BresMed/Lumanity, and BMO Capital Markets. The firm holds no patents, has no disclosed external institutional funding, and reports a headcount in the 11-50 range, with leadership concentrated in a small number of Partners and Principals plus a strategic advisor bench. Marketing is conducted primarily through a professional-services website, published case studies, and industry conference participation rather than paid or product-led channels.

By stated metrics, Maple has contributed to over 150 peer-reviewed manuscripts and poster presentations since 2015, served clients across the US, UK, EU5, and Japan, and reported in published case studies that clients renewed engagement for three subsequent years on prior workstreams. No revenue, customer logos, or contract values are publicly disclosed.

Short descriptiontext

Maple Health Group is a global strategy consulting firm founded in 2015 and headquartered in New York that delivers Health Economics and Market Access advisory services - including economic modeling, evidence synthesis, HTA submissions, and value communications - to pharmaceutical, biotechnology, and medical device companies across the US, Europe, and Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
health economics consulting, market access strategy, health technology assessment, evidence generation planning, value demonstration consulting
NAICS code2 codes
  • Management Consulting Services54161
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Management Consulting Services8742
  • Services-Commercial Physical & Biological Research8731
Product category
Health Economics & Market Access Consulting
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Strategic Health Economics Consulting
TypeProfessional Services
Description

Project-based consulting engagements providing Health Economics and Market Access strategy services to pharmaceutical, biotech, and medical device companies. Engagements include evidence generation planning, economic modelling, HTA strategy development, and value communications development.

maplehealthgroup.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Maple Health Group is a global strategy consulting firm delivering Health Economics and Market Access (HEOR) services to pharmaceutical, biotechnology, and medical device companies. Its practice spans market access and value strategy (landscape assessments, evidence generation planning, payer research), economic modelling and evidence synthesis (cost-effectiveness/budget impact/microsimulation models, network meta-analyses), and value communications (global value dossiers, AMCP dossiers, payer value propositions, scientific publications).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 150+ peer-reviewed manuscripts and poster presentations contributed to since 2015
+1 more record
Product overview1 text field

Maple Health Group is a global strategy consulting firm offering a unified portfolio of Health Economics and Market Access consulting services. The core offering consists of three integrated service lines: Market Access & Value Strategy (evidence generation planning, payer research, HTA engagement), Economic Modelling & Evidence Synthesis (cost-effectiveness models, budget impact models, microsimulation, NMAs, MAICs), and Value Communications (global value dossiers, AMCP dossiers, publications). These services are delivered through specific sub-products including analogue pricing monitoring, cost-utility modeling, network meta-analysis, and value demonstration strategy. The interconnected nature of these offerings allows clients to receive end-to-end support from evidence generation through to payer communications.

Product and service8 records
1Market Access & Value Strategy
CategoryMarket Access Consulting
Description

Strategic consulting service for pharmaceutical, biotech, and medical device companies that identifies opportunities to demonstrate product value and optimize global market access through therapeutic area landscape assessments, strategic evidence generation plans, payer research, and dynamic market access trainings.

2Economic Modelling & Evidence Synthesis
CategoryHealth Economic Modelling
Description

Strategic consulting service providing value demonstration to policymakers through economic models, evidence synthesis and real-world evidence; includes Health Economics and HTA strategy development, cost-effectiveness/budget impact models, microsimulation models, systematic literature reviews, and network meta-analyses.

3Value Communications
CategoryValue Communications Consulting
Description

Strategic communication service for pharmaceutical, biotech, and medical device clients that develops publications and conference materials, payer value propositions and value messages, and industry-insight newsletters to demonstrate product value across stakeholder audiences.

4AMCP Dossier Development
CategoryValue Communications Consulting
Description

Development of AMCP dossiers to support US payer formulary decision-making, including targeted literature search, dossier drafting with annotations, and internal review support with medical and legal teams, for pharmaceutical manufacturers.

5Analogue Pricing and Access Monitoring
CategoryMarket Access Monitoring
Description

Monthly monitoring service providing access, pricing, and HTA decisions tracking for competitor products across US and EU5 markets, delivered via XLS and web-based tools with strategic recommendations on pricing and market access for pharmaceutical and biotech clients.

6Cost-Utility and Budget Impact Modeling
CategoryHealth Economic Modelling
Description

Development of cost-utility and budget impact models to communicate the economic value of pharmaceutical products, including technical documents supporting NICE submission (UK) and AMCP dossier (US).

7Indirect Treatment Comparison / Network Meta-Analysis
CategoryEvidence Synthesis
Description

Indirect treatment comparison service using network meta-analysis to assess clinical value of products, including systematic literature review, statistical analysis plan development, and Bayesian network meta-analysis for pharmaceutical and biotech clients.

8Value Demonstration Strategy
CategoryMarket Access Consulting
Description

Payer-focused evidence generation planning service delivering aspirational value proposition development, secondary and primary research validation with HTA members and US payers, and strategic recommendations for market access for pharmaceutical and biotech clients.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key highlights14 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Maple Health Group

Health Economics & Market Access Consultingmaplehealthgroup.com

Maple Health Group is a global strategy consulting firm founded in 2015 and headquartered in New York that delivers Health Economics and Market Access advisory services - including economic modeling, evidence synthesis, HTA submissions, and value communications - to pharmaceutical, biotechnology, and medical device companies across the US, Europe, and Asia.

What Maple Health Group does

Maple Health Group is a global strategy consulting firm founded in 2015 and headquartered in New York, specializing in Health Economics and Market Access (HEOR) advisory services for pharmaceutical, biotechnology, and medical device companies. The firm is organized around three integrated service lines: Market Access and Value Strategy (therapeutic-area landscape assessments, strategic evidence generation planning, payer research, and market access training), Economic Modelling and Evidence Synthesis (cost-effectiveness, cost-utility, budget impact and microsimulation models, systematic literature reviews, Bayesian network meta-analyses, MAICs, and HTA strategy and submissions), and Value Communications (global value dossiers, AMCP dossiers, payer value propositions, scientific publications, and conference materials). Underlying technical assets include proprietary Excel/VBA-based economic models, web-based pricing and access monitoring tools, and the co-developed STEER structured expert elicitation methodology that has been referenced by multiple HTA agencies.

The firm generates revenue through project-based, quote-based professional services engagements sold directly to enterprise pharma, biotech, and med-device clients; specific pricing is not publicly disclosed. Delivery is performed by a globally distributed team of senior consultants and PhD-level health economists operating from nearly a dozen countries and fluent in over 15 languages, including former NICE Technology Appraisal Committee members, ex-pharma HEOR leaders from Biogen, Pfizer, Daiichi-Sankyo, J&J, and EMD Serono, and alumni of CBPartners, BresMed/Lumanity, and BMO Capital Markets. The firm holds no patents, has no disclosed external institutional funding, and reports a headcount in the 11-50 range, with leadership concentrated in a small number of Partners and Principals plus a strategic advisor bench. Marketing is conducted primarily through a professional-services website, published case studies, and industry conference participation rather than paid or product-led channels.

By stated metrics, Maple has contributed to over 150 peer-reviewed manuscripts and poster presentations since 2015, served clients across the US, UK, EU5, and Japan, and reported in published case studies that clients renewed engagement for three subsequent years on prior workstreams. No revenue, customer logos, or contract values are publicly disclosed.

Maple Health Group firmographics

Firmographics
Name
Maple Health Group
Legal name
Maple Health Group, LLC
Website
https://maplehealthgroup.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Maple Health Group is a global strategy consulting firm founded in 2015 and headquartered in New York that delivers Health Economics and Market Access advisory services - including economic modeling, evidence synthesis, HTA submissions, and value communications - to pharmaceutical, biotechnology, and medical device companies across the US, Europe, and Asia.
Ownership category
akta.pro rank

Where Maple Health Group is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Maple Health Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Strategic Health Economics Consulting: Project-based consulting engagements providing Health Economics and Market Access strategy services to pharmaceutical, biotech, and medical device companies. Engagements include evidence generation planning, economic modelling, HTA strategy development, and value communications development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Maple Health Group product offering

Product offering

Core offering

Maple Health Group is a global strategy consulting firm delivering Health Economics and Market Access (HEOR) services to pharmaceutical, biotechnology, and medical device companies. Its practice spans market access and value strategy (landscape assessments, evidence generation planning, payer research), economic modelling and evidence synthesis (cost-effectiveness/budget impact/microsimulation models, network meta-analyses), and value communications (global value dossiers, AMCP dossiers, payer value propositions, scientific publications).

Product overview

Maple Health Group is a global strategy consulting firm offering a unified portfolio of Health Economics and Market Access consulting services. The core offering consists of three integrated service lines: Market Access & Value Strategy (evidence generation planning, payer research, HTA engagement), Economic Modelling & Evidence Synthesis (cost-effectiveness models, budget impact models, microsimulation, NMAs, MAICs), and Value Communications (global value dossiers, AMCP dossiers, publications). These services are delivered through specific sub-products including analogue pricing monitoring, cost-utility modeling, network meta-analysis, and value demonstration strategy. The interconnected nature of these offerings allows clients to receive end-to-end support from evidence generation through to payer communications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Market Access & Value Strategy Strategic consulting service for pharmaceutical, biotech, and medical device companies that identifies opportunities to demonstrate product value and optimize global market access through therapeutic area landscape assessments, strategic evidence generation plans, payer research, and dynamic market access trainings.
  • Economic Modelling & Evidence Synthesis Strategic consulting service providing value demonstration to policymakers through economic models, evidence synthesis and real-world evidence; includes Health Economics and HTA strategy development, cost-effectiveness/budget impact models, microsimulation models, systematic literature reviews, and network meta-analyses.
  • Value Communications Strategic communication service for pharmaceutical, biotech, and medical device clients that develops publications and conference materials, payer value propositions and value messages, and industry-insight newsletters to demonstrate product value across stakeholder audiences.
  • AMCP Dossier Development Development of AMCP dossiers to support US payer formulary decision-making, including targeted literature search, dossier drafting with annotations, and internal review support with medical and legal teams, for pharmaceutical manufacturers.
  • Analogue Pricing and Access Monitoring Monthly monitoring service providing access, pricing, and HTA decisions tracking for competitor products across US and EU5 markets, delivered via XLS and web-based tools with strategic recommendations on pricing and market access for pharmaceutical and biotech clients.
  • Cost-Utility and Budget Impact Modeling Development of cost-utility and budget impact models to communicate the economic value of pharmaceutical products, including technical documents supporting NICE submission (UK) and AMCP dossier (US).
  • Indirect Treatment Comparison / Network Meta-Analysis Indirect treatment comparison service using network meta-analysis to assess clinical value of products, including systematic literature review, statistical analysis plan development, and Bayesian network meta-analysis for pharmaceutical and biotech clients.
  • Value Demonstration Strategy Payer-focused evidence generation planning service delivering aspirational value proposition development, secondary and primary research validation with HTA members and US payers, and strategic recommendations for market access for pharmaceutical and biotech clients.

Quantifiable outcome

  • 150+ peer-reviewed manuscripts and poster presentations contributed to since 2015
  • +1 more outcomes

Companies that use Maple Health Group

Customer profile

Segments3 records

Ideal customer profiles3 records

Maple Health Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Maple Health Group partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Maple Health Group competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key highlights14 records

Customer concentration

Maple Health Group social profiles

Digital presence

Maple Health Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Maple Health Group leadership team

Management profile

Number of profiles

Profiles10 records

Maple Health Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Maple Health Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maple Health Group

What does Maple Health Group do?

Maple Health Group is a global strategy consulting firm delivering Health Economics and Market Access (HEOR) services to pharmaceutical, biotechnology, and medical device companies. Its practice spans market access and value strategy (landscape assessments, evidence generation planning, payer research), economic modelling and evidence synthesis (cost-effectiveness/budget impact/microsimulation models, network meta-analyses), and value communications (global value dossiers, AMCP dossiers, payer value propositions, scientific publications).

Is Maple Health Group a public or private company?

Maple Health Group is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Maple Health Group founded?

Maple Health Group was founded in 2015. It employs 51 to 100 people.

Where is Maple Health Group based?

Maple Health Group is headquartered in New York, United States, in the North America region.

How does Maple Health Group make money?

One revenue line is on record: strategic Health Economics Consulting.

Does Maple Health Group have an API?

No public API is recorded for Maple Health Group.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales